Cargando…

FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2

MOTIVATION: The novel coronavirus (SARS-CoV-2) currently spreads worldwide, causing the disease COVID-19. The number of infections increases daily, without any approved antiviral therapy. The recently released viral nucleotide sequence enables the identification of therapeutic targets, e.g. by analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Renz, Alina, Widerspick, Lina, Dräger, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Systems
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773487/ https://www.ncbi.nlm.nih.gov/pubmed/33381848 http://dx.doi.org/10.1093/bioinformatics/btaa813

Ejemplares similares

Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target
por: Renz , Alina, et al.
Publicado: (2021)

First Genome-Scale Metabolic Model of Dolosigranulum pigrum Confirms Multiple Auxotrophies
por: Renz, Alina, et al.
Publicado: (2021)

New workflow predicts drug targets against SARS-CoV-2 via metabolic changes in infected cells
por: Leonidou, Nantia, et al.
Publicado: (2023)

Antiviral Activity of Nitrosonium Cations against SARS-CoV-2 on a Syrian Hamster Model
por: Shipovalov, A. V., et al.
Publicado: (2022)

popFBA: tackling intratumour heterogeneity with Flux Balance Analysis
por: Damiani, Chiara, et al.
Publicado: (2017)

Population FBA predicts metabolic phenotypes in yeast
por: Labhsetwar, Piyush, et al.
Publicado: (2017)

Validation of an FBA model for Pichia pastoris in chemostat cultures
por: Morales, Yeimy, et al.
Publicado: (2014)

Understanding FBA Solutions under Multiple Nutrient Limitations
por: van Pelt-KleinJan, Eunice, et al.
Publicado: (2021)

Antiviral drugs against SARS-CoV-2
por: Aiello, Tommaso Francesco, et al.
Publicado: (2022)

Curating and comparing 114 strain-specific genome-scale metabolic models of Staphylococcus aureus
por: Renz, Alina, et al.
Publicado: (2021)

Global connectivity in genome-scale metabolic networks revealed by comprehensive FBA-based pathway analysis
por: Gao, Yajie, et al.
Publicado: (2021)

FBA Ecological Guild: Trio of Firmicutes-Bacteroidetes Alliance against Actinobacteria in Human Oral Microbiome
por: Li, Wendy, et al.
Publicado: (2020)

Incorporation of enzyme concentrations into FBA and identification of optimal metabolic pathways
por: De, Rajat K, et al.
Publicado: (2008)

Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2
por: Tonk, Miray, et al.
Publicado: (2021)

Antiviral Effect of Budesonide against SARS-CoV-2
por: Heinen, Natalie, et al.
Publicado: (2021)

Theory and reality of antivirals against SARS-CoV-2
por: Zhao, Bo, et al.
Publicado: (2021)

Antiviral Efficacy of Pralatrexate against SARS-CoV-2
por: Bae, Joon-Yong, et al.
Publicado: (2021)

Structure of Staphylococcus aureus guanylate monophosphate kinase
por: El Omari, Kamel, et al.
Publicado: (2006)

Antiviral Activity of Zinc Oxide Nanoparticles against SARS-CoV-2
por: Wolfgruber, Stella, et al.
Publicado: (2023)

FBA-SimVis: interactive visualization of constraint-based metabolic models
por: Grafahrend-Belau, Eva, et al.
Publicado: (2009)

Escher-FBA: a web application for interactive flux balance analysis
por: Rowe, Elliot, et al.
Publicado: (2018)

Multi-Objective Optimization of Microalgae Metabolism: An Evolutive Algorithm Based on FBA
por: Briones-Baez, Monica Fabiola, et al.
Publicado: (2022)

Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro
por: Raymonda, M.H., et al.
Publicado: (2022)

Potential Antiviral Options against SARS-CoV-2 Infection
por: Ianevski, Aleksandr, et al.
Publicado: (2020)

In Vitro Antiviral Activity of Doxycycline against SARS-CoV-2
por: Gendrot, Mathieu, et al.
Publicado: (2020)

Lack of antiviral activity of darunavir against SARS-CoV-2
por: De Meyer, Sandra, et al.
Publicado: (2020)

First-generation oral antivirals against SARS-CoV-2
por: Sendi, Parham, et al.
Publicado: (2022)

Potential antiviral peptides against the nucleoprotein of SARS-CoV-2
por: Mahdi, Iktedar, et al.
Publicado: (2022)

Potential antiviral effects of pantethine against SARS-CoV-2
por: Abou-Hamdan, M., et al.
Publicado: (2023)

SARS-CoV-2 strategically mimics proteolytic activation of human ENaC
por: Anand, Praveen, et al.
Publicado: (2020)

SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
por: Elshabrawy, Hatem A.
Publicado: (2020)

Development of an HPLC-based guanosine monophosphate kinase assay and application to Plasmodium vivax guanylate kinase
por: Pedro, Liliana, et al.
Publicado: (2019)

Managing uncertainty in metabolic network structure and improving predictions using EnsembleFBA
por: Biggs, Matthew B., et al.
Publicado: (2017)

Response to comment on ‘SARS-CoV-2 suppresses anticoagulant and fibrinolytic gene expression in the lung’
por: Mast, Alan E, et al.
Publicado: (2022)

SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020)

Guanylate-binding protein 1 participates in cellular antiviral response to dengue virus
por: Pan, Wen, et al.
Publicado: (2012)

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2
por: Pizzorno, Andrés, et al.
Publicado: (2020)

Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2
por: Carrouel, F., et al.
Publicado: (2020)

Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
por: Santos, Igor de Andrade, et al.
Publicado: (2020)

An in vitro antiviral activity of iodine complexes against SARS-CoV-2
por: Altaf, Imran, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_31v6i31qbi1s3asdlriem8l7dd